Biotechnology company Earth Science Tech, Inc. (OTCQB: ETST) today announced that it will begin formulating a new full spectrum CBD beverage that will leverage its University of Central Oklahoma Provisional Patent, which is designed to improve immune system functions. “The CBD beverage is a most in the époque of legalization of recreative marijuana. Not only does CBD have positive effects on immune cells, it has strong antioxidant and anti-psychotic properties,” Michel Aube, CEO and CSO of ETST, stated in the news release. “Indeed, it is now well recognized that CBD is an anti-psychotic molecule and that CBD has opposite effect to Δ-9-tetrahydrocannabinol (THC). This is why health professions are concerned by the fact that most marijuana plants have very low concentration of CBD and huge amount of THC molecule. At Earth Science Tech we focused on full spectrum cannabinoids derived from industrial hemp that contains extremely low to no THC since THC is psychoactive causing dependency and mental illness in young individuals. This means that all our products are beneficial for recreational marijuana consumer because it helps them to balance their intake of psychoactive and anti-psychotic cannabinoids. Our cannabinoid products help to counter the side effects of THC in addition of having itself other interesting biological activities like anti-inflammatory and antioxidant properties.”
To view the press release, visit http://cnw.fm/J0KRs
About Earth Science Tech, Inc.
Earth Science Tech, Inc. offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma; in addition to studies through DV Biologics that prove the company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market. For more information, visit the company’s website at www.EarthScienceTech.com
More from PsychedelicNewsBreaks
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) PsychedelicNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. PNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled visibility, recognition and brand awareness. PNW is where news, content and information converge.
To receive instant SMS alerts, text HEMPWIRE to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/disclaimer/
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
NRx Pharmaceuticals (NASDAQ: NRXP) announced it has repaid the remaining $5.4 million of balance sheet…
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, said it amended its Investigational New Drug…
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, said the FDA has received its Abbreviated…
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, said it will host a corporate update…
NRx Pharmaceuticals (NASDAQ: NRXP) said Founder, Chairman and CEO Jonathan Javitt, M.D., M.P.H., will present…
NRx Pharmaceuticals (NASDAQ: NRXP) reported third-quarter 2025 results and outlined progress across its clinical programs,…